Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: Results from the randomized phase iII children's oncology group Trial AAML0531

Alan S. Gamis; Todd A. Alonzo; Soheil Meshinchi; Lillian Sung; Robert B. Gerbing; Susana C. Raimondi; Betsy A. Hirsch; Samir B. Kahwash; Amy Heerema-McKenney; Laura Winter; Kathleen Glick; Stella M. Davies; Patti Byron; Franklin O. Smith; Richard Aplenc

doi:10.1200/JCO.2014.55.3628

Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: Results from the randomized phase iII children's oncology group Trial AAML0531

Alan S. Gamis, Todd A. Alonzo, Soheil Meshinchi, Lillian Sung, Robert B. Gerbing, Susana C. Raimondi, Betsy A. Hirsch, Samir B. Kahwash, Amy Heerema-McKenney, Laura Winter, Kathleen Glick, Stella M. Davies, Patti Byron, Franklin O. Smith, Richard Aplenc

Laboratory Medicine and Pathology

Research output: Contribution to journal › Article › peer-review

345 Scopus citations

Original language	English (US)
Pages (from-to)	3021-3032
Number of pages	12
Journal	Journal of Clinical Oncology
Volume	32
Issue number	27
DOIs	https://doi.org/10.1200/JCO.2014.55.3628
State	Published - Sep 20 2014

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1200/JCO.2014.55.3628

OpenUrl availability

Full text

Cite this

Gamis, A. S., Alonzo, T. A., Meshinchi, S., Sung, L., Gerbing, R. B., Raimondi, S. C., Hirsch, B. A., Kahwash, S. B., Heerema-McKenney, A., Winter, L., Glick, K., Davies, S. M., Byron, P., Smith, F. O., & Aplenc, R. (2014). Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: Results from the randomized phase iII children's oncology group Trial AAML0531. Journal of Clinical Oncology, 32(27), 3021-3032. https://doi.org/10.1200/JCO.2014.55.3628

Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: Results from the randomized phase iII children's oncology group Trial AAML0531. / Gamis, Alan S.; Alonzo, Todd A.; Meshinchi, Soheil et al.
In: Journal of Clinical Oncology, Vol. 32, No. 27, 20.09.2014, p. 3021-3032.

Research output: Contribution to journal › Article › peer-review

Gamis, AS, Alonzo, TA, Meshinchi, S, Sung, L, Gerbing, RB, Raimondi, SC, Hirsch, BA, Kahwash, SB, Heerema-McKenney, A, Winter, L, Glick, K, Davies, SM, Byron, P, Smith, FO & Aplenc, R 2014, 'Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: Results from the randomized phase iII children's oncology group Trial AAML0531', Journal of Clinical Oncology, vol. 32, no. 27, pp. 3021-3032. https://doi.org/10.1200/JCO.2014.55.3628

Gamis AS, Alonzo TA, Meshinchi S, Sung L, Gerbing RB, Raimondi SC et al. Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: Results from the randomized phase iII children's oncology group Trial AAML0531. Journal of Clinical Oncology. 2014 Sep 20;32(27):3021-3032. doi: 10.1200/JCO.2014.55.3628

@article{9959d96b0fcf4798928fa136a39823a2,

title = "Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: Results from the randomized phase iII children's oncology group Trial AAML0531",

author = "Gamis, {Alan S.} and Alonzo, {Todd A.} and Soheil Meshinchi and Lillian Sung and Gerbing, {Robert B.} and Raimondi, {Susana C.} and Hirsch, {Betsy A.} and Kahwash, {Samir B.} and Amy Heerema-McKenney and Laura Winter and Kathleen Glick and Davies, {Stella M.} and Patti Byron and Smith, {Franklin O.} and Richard Aplenc",

year = "2014",

month = sep,

day = "20",

doi = "10.1200/JCO.2014.55.3628",

language = "English (US)",

volume = "32",

pages = "3021--3032",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "American Society of Clinical Oncology",

number = "27",

}

TY - JOUR

T1 - Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk

T2 - Results from the randomized phase iII children's oncology group Trial AAML0531

AU - Gamis, Alan S.

AU - Alonzo, Todd A.

AU - Meshinchi, Soheil

AU - Sung, Lillian

AU - Gerbing, Robert B.

AU - Raimondi, Susana C.

AU - Hirsch, Betsy A.

AU - Kahwash, Samir B.

AU - Heerema-McKenney, Amy

AU - Winter, Laura

AU - Glick, Kathleen

AU - Davies, Stella M.

AU - Byron, Patti

AU - Smith, Franklin O.

AU - Aplenc, Richard

PY - 2014/9/20

Y1 - 2014/9/20

UR - http://www.scopus.com/inward/record.url?scp=84907192040&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907192040&partnerID=8YFLogxK

U2 - 10.1200/JCO.2014.55.3628

DO - 10.1200/JCO.2014.55.3628

M3 - Article

C2 - 25092781

AN - SCOPUS:84907192040

SN - 0732-183X

VL - 32

SP - 3021

EP - 3032

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

IS - 27

ER -

Gemtuzumab ozogamicin in children and adolescents with de novo acute myeloid leukemia improves event-free survival by reducing relapse risk: Results from the randomized phase iII children's oncology group Trial AAML0531

UN SDGs

Access

OpenUrl availability

Other files and links

Cite this